Home > Riviste > Gazzetta Medica Italiana Archivio per le Scienze Mediche > Fascicoli precedenti > Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2019 January-February;178(1-2) > Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2019 January-February;178(1-2):1-8

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

ORIGINAL ARTICLE   

Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2019 January-February;178(1-2):1-8

DOI: 10.23736/S0393-3660.18.03709-9

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Concomitant use of policosanol and antiplatelet drugs in older patients

Julio C. FERNÁNDEZ-TRAVIESO 1 , José ILLNAIT-FERRER 1, Lilia FERNÁNDEZ-DORTA 1, Rosa MÁS-FERREIRO 1, Sarahí MENDOZA-CASTAÑO 1, Ernesto LÓPEZ-GONZÁLEZ 2, Rafael GÁMEZ-MENÉNDEZ 1, Meilis MESA-ANGARICA 2

1 National Center for Scientific Research, Havana, Cuba; 2 Surgical Medical Research Center, Havana, Cuba



BACKGROUND: The objective of the present analysis as a part of a prevention study, we investigated whether policosanol administered to older individuals taking antiplatelet drugs supposes concern regarding to potential risk for adverse drug-drug interactions.
METHODS: We randomized 1470 elderly patients at high coronary risk to policosanol 5 mg/day or placebo for 3 years. For this analysis, the records of all patients (N.=334) taking antiplatelet drugs were included. Analysis was by intention-to-treat.
RESULTS: After one year, policosanol decreased significantly low-density lipoprotein-cholesterol (LDL-C) (21.0%), total cholesterol (16.9%) and triglycerides (19.6%), while raised high-density lipoprotein-cholesterol (HDL-C) (6.2%). Policosanol effects were maintained, even improved, during the follow-up. At study completion policosanol lowered LDL-C (34.3%), total cholesterol (23.9%), triglycerides (22.2%) and raised HDL-C (14.5%). Sixty patients (41 placebo, 19 policosanol, P<0.01) withdrew from the study, 33 (23 placebo, 10 policosanol) (P<0.01) due to some adverse event, all serious. Policosanol did not impair safety indicators and did not increase any adverse event respect to placebo.
CONCLUSIONS: The policosanol can be administered to older patients taking antiplatelet drugs without risk of relevant adverse drug-drug interactions.


KEY WORDS: Policosanol - Platelet aggregation inhibitors - Aged - Drug interactions - Drug-related side effects and adverse reactions

inizio pagina